Cigna (CI) will drop coverage of GLP-1 obesity drugs Wegovy and Zepbound from its own employee health plan on July 1, a move that spotlights mounting cost pressure on a drug category generating billions in annual revenue for Novo Nordisk and Eli Lilly.
For long-horizon investors, the decision by one of America’s largest health insurers to exclude the drugs from its own workforce plan – even as it sells GLP-1 coverage solutions to corporate clients – raises pointed questions about the sustainable demand ceiling for semaglutide and tirzepatide at current net prices.1
Key Takeaways
- Cigna ends GLP-1 obesity coverage for employees effective July 1.
- List prices for Wegovy and Zepbound exceed $1,100-$1,350 per month.
- Only half of Cigna’s employer clients currently cover GLP-1 weight-loss drugs.
Market Context & Cost Backdrop
Wegovy carries a list price of roughly $1,350 per month, while Zepbound lists at approximately $1,100 per month; average net prices – after rebates – stood at $616 and $725 respectively as of March, according to analysis by the Institute for Clinical and Economic Review.2 Those figures still dwarf the per-member-per-month cost of most other specialty drugs, and the numbers explain why only about half of Cigna’s employer clients currently offer GLP-1 obesity coverage at all.2
The insurer’s internal plan reversal follows a broader employer pullback: a January 2026 report noted that companies across the United States were dropping GLP-1 obesity coverage as costs escalated.3 Cigna’s decision puts it alongside a growing cohort of self-insured employers who have concluded that the drugs’ budget impact outweighs near-term clinical benefit.
Detailed Analysis: A Credibility Question for the GLP-1 Bull Case
The signal is structurally significant because Cigna simultaneously markets GLP-1 access programmes to external clients through its Evernorth pharmacy-benefits unit, which in May 2025 struck a deal with Eli Lilly (LLY) and Novo Nordisk (NVO) to cap employee out-of-pocket costs at $200 per month for Wegovy and Zepbound.2 That deal was designed to entice the roughly 50% of Evernorth clients that were not yet covering the drugs.
Evernorth Senior Vice President of Pharmacy Relations Harold Carter said at the time that clients already covering GLP-1s for weight loss could expect “up to almost 20% reduction in their costs” under the updated arrangement with the two manufacturers.2 Yet Cigna’s decision to exclude the drugs for its own staff suggests that even discounted net prices remain difficult to justify on a pure cost-benefit basis for many plan sponsors.
The dynamic highlights a structural tension in the GLP-1 demand story: pharmaceutical revenue forecasts assume broad and sustained employer uptake, but the employer base is proving far more price-sensitive than the bull case implies.4 Medicare negotiated rates for Ozempic and Wegovy under the Inflation Reduction Act are set to take effect in 2027, which analysts expect to compress net prices further and reshape commercial market dynamics.2
Pipeline & Competitive Implications
CVS Caremark’s decision in May 2025 to designate Wegovy as its preferred weight-loss drug – effectively deprioritising Zepbound – added formulary complexity that Evernorth sought to sidestep by maintaining dual preferred status for both branded drugs.2 Cigna’s internal plan exclusion does not change that commercial formulary strategy, but it may embolden other large self-insured employers to follow suit, tightening the addressable market.
Ben Ippolito, senior fellow in health economics at the American Enterprise Institute, said Medicare price negotiations will force Eli Lilly’s hand competitively: “Once the drug is negotiated, it must be featured on formulary in Medicare. And so that means that if you’re Eli Lilly, you have to try and compete in the Medicare market with a product that’s going to be on formulary and have an artificially lower price. And so it’s going to filter through to what Eli Lilly does.”2
Outlook
Cigna’s internal plan change, effective July 1, is limited to the company’s own employee benefit programme and does not alter the formulary options it administers for external employer clients.1 However, the move is likely to be watched closely by plan sponsors weighing their own 2027 benefit decisions, given that Evernorth’s new pricing programme for employers was itself launched only in the second half of 2025.2
For investors holding positions in Novo Nordisk or Eli Lilly on the thesis of a secular GLP-1 supercycle, the Cigna disclosure reinforces that employer-side demand remains the critical variable – and that the path to mass adoption hinges on net-price reductions that neither manufacturer has yet fully delivered at scale.2, 4
Not investment advice. For informational purposes only.
References
1(Jul 17, 2025). “Overview | Cigna Healthcare Newsroom”. Cigna Healthcare Newsroom. Retrieved June 2, 2026.
2Bertha Coombs (May 21, 2025). “Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs”. CNBC. Retrieved June 2, 2026.
3(Jan 15, 2026). “Employers across America are dropping GLP-1 weight loss drug coverage as costs escalate”. NewsChannel5 via Facebook. Retrieved June 2, 2026.
4“Weight Loss Management | Cigna Healthcare”. Cigna Healthcare Insights. Retrieved June 2, 2026.
5“Weight-Loss Medicines | Cigna”. Cigna.com. Retrieved June 2, 2026.